Corrigendum to “A systematic review of higher-risk myelodysplastic syndromes clinical trials to determine the benchmark of azacitidine and explore alternative endpoints for overall survival” [Leukemia Res. 104 March (2021)]
Titel:
Corrigendum to “A systematic review of higher-risk myelodysplastic syndromes clinical trials to determine the benchmark of azacitidine and explore alternative endpoints for overall survival” [Leukemia Res. 104 March (2021)]
Auteur:
Garcia, Jacqueline S. Swords, Ronan T. Roboz, Gail J. Jacoby, Meagan A. Garcia-Manero, Guillermo Hong, Wan-Jen Yang, Xiaoqing Zhou, Ying Platzbecker, Uwe Steensma, David P. Wolff, Johannes E. Fenaux, Pierre